Brief: Imunon Inc Preclinical Data Showing Strong Immunogenicity And Protection With Co's Placcine DNA-Based Vaccines Modality
Brief: Imunon Inc Reports Net Loss For Q1 Of 2023 Of $0.68 Per Share
Imunon Inc expected to post a loss of 65 cents a share - Earnings Preview
Imunon Inc reports results for the quarter ended in December - Earnings Summary
Brief: IMUNON Reports 2022 Loss Per Share Of $5.03
Imunon Inc expected to post a loss of 85 cents a share - Earnings Preview
Brief: Imunon And Break Through Cancer Commence Enrollment In A Phase 1/2 Clinical Study Of Imnn-001 In Combination With Avastin In Advanced Ovarian Cancer
Brief: Imunon Receives $1.6 Mln From Sale Of Its New Jersey Net Operating Losses
Brief: Imunon Enters Into Collaborative Research Agreement With The Wistar Institute’S Vaccine & Immunotherapy Center To Research Imunon’S Placcine Vaccine Platform
Brief: Imunon Reports Q3 Financial Results, Provides Business Update
Imunon Inc reports results for the quarter ended in September - Earnings Summary
Imunon Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: Imunon Enters Into Technology Evaluation Agreement With Acuitas Therapeutics
Brief: Imunon Appoints James E. Dentzer To Its Board Of Directors
Brief: Celsion Corp Announces Company Name Change To Imunon Inc
Brief: Celsion Completes Enrollment Of Phase I/II Ovation 2 Study With Gen-1 In Advanced Ovarian Cancer
Brief: Celsion Corporation Highlights Progress In DNA-Based Vaccine Program
Celsion Corp reports results for the quarter ended in June - Earnings Summary
Brief: Celsion Corporation reports Q2 results